Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

CCR6 antagonist PF-07054894 for autoimmune disorders

Aug. 31, 2021

Adjuvance reports interim phase I data on next-generation saponin adjuvant TQL-1055

Aug. 25, 2021

BlueWillow announces interim phase I data on intranasal anthrax vaccine candidate BW-1010

Aug. 24, 2021

Bavarian Nordic studies ABNCoV2 as COVID-19 booster vaccine in phase II

Aug. 23, 2021

Shanghai Bowei Biological Technology, collaborators divulge polynucleotides for expressing HPV 51L1

Aug. 23, 2021

First patient dosed with CIT-013, a first-in-class antagonist targeting NETs

Aug. 18, 2021

Polymer-mediated "immunocloaking" - A new paradigm for combating transplant rejection?

Aug. 16, 2021

SARS-CoV-2 spike ectodomain protein StriFK vaccine with adjuvant reduces transmission in animals

Aug. 13, 2021

Cogent initiates phase II study of CGT-9486 in systemic mastocytosis

Aug. 13, 2021

Equillium presents additional data from EQUALISE study of itolizumab

Aug. 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...